How fake drugs, Jan Aushadhi push are eating away the profits of top pharma companies

“Tempers are flaring up easily at our cycle meetings,” says an exasperated Ajay Kumar (name changed), a medical representative in his thirties. Meeting targets have never been this tough, he says, referring to the reviews by his managers. Last few months, particularly, are causing worries as his Mumbai-based company has sent aggressive signals to find new ways to shore up prescription volumes.

Kumar’s state may echo across the pharmaceutical.